Janssen Research & Development, Llc

This study tests two drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivantamab with c…

This study tests whether adding the experimental drug bleximenib to standard medicines (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. It includes 600 adults aged 18 and older who are new…

This study tests a new medicine called nipocalimab against a standard treatment (IVIG) in 50 pregnant women whose babies are at risk for a rare condition that causes low platelets and severe bleeding. The goal is to see if nipocalimab can better prevent death or serious bleeding …

This study tests a subcutaneous (under-the-skin) form of the drug amivantamab in people with advanced EGFR-mutated non-small cell lung cancer. About 520 participants will receive the drug in different combinations to see if it shrinks tumors and how safe it is. The goal is to con…

This study tests a drug called nipocalimab to see if it can prevent severe bleeding or death in unborn babies with a rare condition called FNAIT, where the mother's immune system attacks the baby's platelets. Pregnant women who have had a previous pregnancy affected by FNAIT are …

This study tests a drug called nipocalimab in adults with generalized myasthenia gravis, a condition that causes muscle weakness. About 199 participants will receive either the drug or a placebo to see if it improves daily activities like talking, chewing, and breathing. The goal…

This study tests a drug called guselkumab in 120 children with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms over 52 weeks. Participants must have active disease confirmed by endoscopy. This is a phase 3 trial, meani…

This study tests a new treatment called TAR-210 for people with a high-risk type of bladder cancer that has a specific genetic change (FGFR alteration). Participants have already received standard BCG therapy. The study compares TAR-210 to standard chemotherapy placed directly in…

This study tests a drug called nipocalimab in children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug safely lowers harmful antibodies and improves daily activities. About 12 children will receive the drug,…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier trials for geographic atrophy, a form of advanced age-related macular degeneration. The goal is to check long-term safety by monitoring eye health and side effects over time. Abou…

This study tests a drug called bedaquiline, given together with other TB medicines, in children and teens (birth to under 18 years) who have multidrug-resistant tuberculosis (MDR-TB) of the lungs. The goal is to see how safe the drug is, how the body processes it, and whether it …

This study tests a drug called nipocalimab in adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. The goal is to see if nipocalimab can delay or prevent relapses compared to a placebo. About 201 participants wi…

This study compares a new drug delivery system (TAR-210) to standard chemotherapy for people with a specific type of bladder cancer that hasn't invaded muscle. The treatment is placed directly into the bladder. About 641 participants will be randomly assigned to receive either TA…

This study tests a new way to deliver the drug erdafitinib directly into the bladder using a special system called TAR-210. It is for people with bladder cancer that has not spread into the muscle layer or has spread into it. The goal is to find the best dose and see if it is saf…

This study looks at different ways to give the drug ibrutinib to people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Some participants will also get another drug called venetoclax. The goal is to see if lowering the dose early or changing it based on…

This study tests whether nipocalimab can reduce lupus disease activity better than a placebo. About 600 adults with moderate to severe lupus will receive either the drug or a placebo for 52 weeks. The main goal is to see if more people on nipocalimab achieve a meaningful reductio…

This study is testing a new oral medication called icotrokinra for adults and adolescents with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. The main goal is to see if the drug can safely bring the disease into remission and keep it under control ov…

This study tests a drug called seltorexant for people with major depression who also have trouble sleeping and haven't gotten enough help from their current antidepressant. About 752 adults and elderly will take either seltorexant or a placebo pill alongside their usual antidepre…

This study tests whether seltorexant, a drug that targets sleep, can improve depressive symptoms in 600 adults with major depression and insomnia. Participants receive either the drug or a placebo for several weeks, then all may receive the drug long-term. The goal is to see if t…

This study tests if certain preventive treatments can reduce or prevent taste changes caused by a multiple myeloma drug called talquetamab. About 210 people with multiple myeloma will be randomly assigned to different preventive strategies. The goal is to improve quality of life …

This study is a global registry that will follow about 175 pregnant people who are at risk for hemolytic disease of the fetus and newborn (HDFN), a condition where the mother's and baby's blood types don't match, causing the baby's red blood cells to break down too fast. Research…

This study follows about 295 people with multiple myeloma who have already received the cell therapy cilta-cel. The goal is to watch for delayed side effects, such as new cancers, nerve problems, or serious infections. No new treatment is given—participants are simply monitored o…